EP08.02-017 Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data

Abstract

Clinical trials have established the role of tyrosine kinase inhibitor (TKI) targeted therapy for metastatic non-small cell lung cancer (mNSCLC) patients with driver mutation, but real-world data are limited. We describe time on treatment (rwTOT) for first-line (1L) mNSCLC patients with EGFR mutation in a 2.5-million-member state-mandated health provider in Israel.